Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ImmuNovation

Financiado

Cerrado

Modular Targeted Nanoplatform for Immune Cell Regulation and Therapy

Cancer is a major cause of disability and mortality worldwide. The striking rise of immunotherapies has transformed the way we prevent and treat cancer. Nevertheless, despite the promising clinical results of immunotherapies, they... ver más

30/09/2024

TAU

Presupuesto desconocido

Líder del proyecto

TEL AVIV UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-09-30

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2 Objective:Objectives:

I+D

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

TAU

Lider

Proyectos interesantes

iNANOVAC4CANCER

Medical Technol...

Nanotechnology

150K€ Cerrado

ONCOTHERANOSTICS

Nanotechnology

Medical Technol...

257K€ Cerrado

CellularNanoMachines

Nanotechnology

Medical Technol...

241K€ Cerrado

PATHFINDER

Medical Technol...

Nanotechnology

2M€ Cerrado

PCIN-2016-025

Medical Technol...

Nanotechnology

100K€ Cerrado

PRECIOUS

Medical Technol...

Nanotechnology

8M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 17 meses Fecha Inicio: 2023-04-01
Fecha Fin: 2024-09-30

Líder del proyecto

TEL AVIV UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer is a major cause of disability and mortality worldwide. The striking rise of immunotherapies has transformed the way we prevent and treat cancer. Nevertheless, despite the promising clinical results of immunotherapies, they suffer from multiple limitations, including manufacturing challenges, limited efficacy, toxicity, and high costs. Recent data highlight the promising role of personalized cancer vaccines in inducing effective antitumor immunity in patients suffering from aggressive forms of cancer. However, systems suitable for targeted delivery of multiple agents required for long-lasting patient immunity are required. ImmuNovation is focused on TNM (Targeted Nano-immunoModulator), a multifunctional dendritic cell-targeted nanovaccine designed to regulate the function and phenotype of immune cells with a pivotal role in the induction of an effective, specific, and long-lasting antitumor immunity. Here, we will evaluate the technical and commercial viability of our novel nanoplatform (developed during my ERC Advanced Grant, 3DBrainStrom) for the targeted therapy of various cancer types. As proof of concept, we will focus on immunotherapy for CEACAM5+ gastrointestinal (GI) cancers, which affect more than 4.8 million new cases per year and cause 3.4 million related deaths worldwide. The nanovaccine will introduce CEACAM5 antigens and various immune modulators with synergistic mechanisms of action to dendritic cells, thus boosting the immune system’s ability to recognize and destroy GI cancer cells. The proposed nanoplatform represents an affordable alternative to current immunotherapies, with enhanced tumour selectivity, efficacy, and safety profile. My vision is that our nanovaccines will change the landscape of the standard of care for many cancer types. Our platform offers a highly attractive business case, as biotechnology and pharmaceutical companies heavily invest in cancer vaccines due to the need for cancer prevention and therapeutic strategies.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores